OBJECTIVE: We evaluated the effect of two calcium channel blockers, verapamil and felodipine, on heart rate variability in hypertensive patients. DESIGN: Time and frequency domain measures of heart rate variability were obtained from 24 h Holter recording in 25 previously untreated hypertensive patients without left ventricular hypertrophy, before and after 3 months of verapamil slow-release treatment (240 mg once daily) or felodipine extended-release treatment (10 mg once daily). RESULTS: Blood pressure values decreased with both drugs. Measures of heart rate variability, comparable at baseline in the two groups, were unchanged after felodipine. After verapamil, the average RR interval, the square root of the mean of the squared differen...
Baseline heart rate is becoming recognized as a predictor of cardiovascular risk. Various antihypert...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
To evaluate the effects of Verapamil and Metoprolol on improving heart rate variability(HRV) in pati...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The short- and long-term effects of two calcium channel blocking drugs, verapamil and nifedipine, on...
Background and Objectives: Efonidipine hydrochloride, an L- and T-type dual calcium channel blocker,...
<div><p>Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability,...
Rate control of atrial fibrillation (AF) is a main treatment modality. However, data are scarce on t...
Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variabili-ty, and al...
Baseline heart rate is becoming recognized as a predictor of cardiovascular risk. Various antihypert...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
Aims To compare the effects of two long-acting calcium antagonists of different types on cardiovascu...
To evaluate the effects of Verapamil and Metoprolol on improving heart rate variability(HRV) in pati...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine...
The short- and long-term effects of two calcium channel blocking drugs, verapamil and nifedipine, on...
Background and Objectives: Efonidipine hydrochloride, an L- and T-type dual calcium channel blocker,...
<div><p>Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability,...
Rate control of atrial fibrillation (AF) is a main treatment modality. However, data are scarce on t...
Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variabili-ty, and al...
Baseline heart rate is becoming recognized as a predictor of cardiovascular risk. Various antihypert...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...
ObjectiveTo investigate heart rate differences between non-dihydropyridine calcium channel blockers ...